Pfizer (PFE) Eyes Potential in Protalix BioTherapeutics (PLX); Chemed (CHE) Soars on Solid Growth


Shares of Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) climbed more than 21% to touch the $1.25 mark during Friday’s trading session after pharmaceutical giant Pfizer Inc. (NYSE:PFE) disclosed in an SEC filing ( SC 13G ) a 5.7% passive stake (5,649,079 shares) in the company. Pfizer recently acquired its position in Protalix for $10 million as part of a collaboration deal between the companies

PLX stock finally closed at $1.12, up $0.09 (or +8.74%) from the previous day’s closing, with a total volume of 659,256 shares traded

Protalix BioTherapeutics, a biopharmaceutical company, has 93.74M Shares Outstanding, Market Capitalization (intraday) of $104.99M and PLX stock 52-week range is $0.95 to $2.40 per share



Chemed Corp. (NYSE:CHE) shares soared $21.15 (or +16.47%) to $149.56 on Friday as the company delivered significant growth in its quarterly financial results, with profit and revenue numbers well-above analysts’ expectations

For the third quarter 2015, Chemed posted revenue of $386 million, a 7.8% increase year over year, and adjusted net income of $30.93 million, or $1.78 per diluted share, compared to adjusted net income of $26.06 million, or $1.48 per diluted share in the same quarter the prior year, exceeding the Capital IQ Consensus Estimate of $1.61 earnings per share on revenues of $376.63 million for the period

CHE stock touched an all-time high of $156.98 in intraday trading, and 582,473 shares of the company exchanged during the day, a large increase in activity versus its average volume (3m) of 180,406

Chemed, which provides hospice and palliative care services in the United States, has 16.92M Shares Outstanding and Market Capitalization (intraday) of $2.53B


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at